The US Food and Drug Administration approved ceftaroline in 2010 for the treatment of community-acquired pneumonia and skin and soft-tissue infections. The most common adverse reactions are diarrhoea, nausea and rash. To present the first case of neutropenia directly related to ceftaroline.
Although neutropenia is a potential cephalosporin class effect, this article presents the first case of neutropenia directly related to ceftaroline. Agranulocytosis and neutropenia are rare, yet potentially life-threatening adverse effects of cephalosporins. Healthcare providers should be aware of the potential for ceftaroline to cause neutropenia, particularly in patients treated for greater than two weeks.
Read more: Ceftaroline
- 5k/8k Run to Stop the Silence of Chid Abuse – April 14, 2013 (arianaleilani.wordpress.com)
- Neutropenic Patients, Like Ariana-Leilani, Are Particularly Vulnerable to Flesh Eating Bacteria (arianaleilani.wordpress.com)
- University of Chicago: Fever and Neutropenia in the Non-Chemotherapy Patient (arianaleilani.wordpress.com)